Use of plasma‐derived factor VIIa in a child with inhibitors of FVIII for the placement of an implantable intravenous access device
- 1 October 1995
- journal article
- Published by Wiley in Haemophilia
- Vol. 1 (4) , 267-269
- https://doi.org/10.1111/j.1365-2516.1995.tb00087.x
Abstract
We treated a 20-month-old boy with severe haemophilia A who developed a high level factor VIII (FVIII) inhibitor. An implantable intravenous access device (IVAD) was safely placed on the lateral chest under anaesthesia using plasma-derived factor VIIa (FVIIa). Implantation of an IVAD into a haemophilic child with an inhibitor requires considerable care, because the area of subdermal invasion is broader than in the implantation of a central venous line. However, placement of an IVAD provides very convenient access to the central venous line and is an appropriate tool for frequent injection, such as the induction of immunotolerance to FVIII.Keywords
This publication has 8 references indexed in Scilit:
- Implantable Intravenous Access Devices in Children With HemophiliaArchives of Pediatrics & Adolescent Medicine, 1994
- Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding DisordersTransfusion Medicine Reviews, 1993
- Experience With Recombinant Factor VIIA in an Infant Hemophiliac With Inhibitors to FVIILC Undergoing Emergency Central Line PlacementJournal of Pediatric Hematology/Oncology, 1993
- A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to PhosphatidylserineThrombosis and Haemostasis, 1993
- Coagulation changes and the influence of the early perfusate in the course of orthotopic liver transplantation (OLT) when aprotinin is used intra-operativelyBlood Coagulation & Fibrinolysis, 1991
- Autoactivation of human recombinant coagulation factor VIIBiochemistry, 1989
- Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low doseBritish Journal of Haematology, 1986